Cargando…

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is overexpressed across a wide range of tumors....

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazha, Bassel, Inal, Cengiz, Owonikoko, Taofeek K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358363/ https://www.ncbi.nlm.nih.gov/pubmed/32733795 http://dx.doi.org/10.3389/fonc.2020.01000

Ejemplares similares

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Erber, Ramona, et al.
Publicado: (2021)

Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin
por: Inagaki, Fuyuki F., et al.
Publicado: (2022)

Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells
por: Wu, Dianna Y., et al.
Publicado: (2003)

Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
por: Nazha, Bassel, et al.
Publicado: (2022)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2
por: Müller, Jan, et al.
Publicado: (2016)

Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD(2) Coated Nanoparticles
por: Tivnan, Amanda, et al.
Publicado: (2012)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

Disialoganglioside GD2 distributes preferentially into substrate- associated microprocesses on human melanoma cells during their attachment to fibronectin
Publicado: (1986)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2
Publicado: (1987)

Pharmacokinetics of the disialoganglioside, G(D2), a circulating tumor biomarker for neuroblastoma, in nonhuman primates
por: Balis, Frank M., et al.
Publicado: (2021)

Role of DNA Methylation in the Resistance to Therapy in Solid Tumors
por: Romero-Garcia, Susana, et al.
Publicado: (2020)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells
por: Lin, Jin-Jin, et al.
Publicado: (2014)

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer
por: Galan, Alba, et al.
Publicado: (2023)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Role of hypoxia in the tumor microenvironment and targeted therapy
por: Chen, Gaoqi, et al.
Publicado: (2022)

Targeted treatment of solid tumors in pediatric precision oncology
por: Bertacca, Ilaria, et al.
Publicado: (2023)

Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor
por: Jiang, Qingzhi, et al.
Publicado: (2019)

Editorial: Evolving roles of piRNAs in solid tumors
por: Ng, Lui, et al.
Publicado: (2023)

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
por: Ortiz, Michael V., et al.
Publicado: (2019)

Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products
por: Logun, Meghan, et al.
Publicado: (2023)

GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015)

Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing
por: An, Sungbin, et al.
Publicado: (2022)

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors
por: Wei, Yaolu, et al.
Publicado: (2022)

The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies
por: Shen, Colette J., et al.
Publicado: (2021)

The Origins and Generation of Cancer-Associated Mesenchymal Stromal Cells: An Innovative Therapeutic Target for Solid Tumors
por: Li, Wei, et al.
Publicado: (2021)

Prognostic role of indoleamine 2,3-dioxygenase 1 expression in solid tumors: A systematic review and meta-analysis
por: Zhang, Haiyan, et al.
Publicado: (2022)

Shp1 in Solid Cancers and Their Therapy
por: Varone, Alessia, et al.
Publicado: (2020)

A novel nomogram based on GD for predicting prognosis in hepatocellular carcinoma
por: Liu, Ying, et al.
Publicado: (2023)

Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma
por: Zakka, Katerina, et al.
Publicado: (2020)

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
por: Das, Millie, et al.
Publicado: (2021)

Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project
por: Belltall, Amparo, et al.
Publicado: (2022)

Editorial: The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility
por: Zhou, Jian-Guo, et al.
Publicado: (2021)

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors
por: Sigaud, Romain, et al.
Publicado: (2021)

Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis
por: Jiang, Kui-Ying, et al.
Publicado: (2023)

Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis
por: Kim, Younghoon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jmneb66nhf62geanhl6acjm7h6